seekingalpha.com · 10 jul

Start Investing At 60 And Retire On Dividends Forever

Retiring on dividends remains achievable for late starters by building a high-yield, quality portfolio targeting a 6% yield with safe, growing payouts. Dividend-focused strategies mitigate sequence of returns risk, enabling investors to live off income rather than depleting principal during market downturns. Examples like Enbridge Inc. (ENB), Omega Healthcare Investors, Inc. (OHI), and Bristol-Myers Squibb Company (BMY) illustrate our buy low, sell high, and get paid to wait principles, delivering strong returns and dividend growth.

fool.com · 7 jul

2 Dirt Cheap Dividend Stocks to Buy With $1,000 Right Now

They may not remain cheap for too much longer.

fool.com · 7 jul

3 High-Yield Dividend Stocks to Buy and Hold Forever (Hint: AbbVie Makes the List)

AbbVie is hitting its stride now that it has transitioned past Humira's patent expiration. Medtronic is a steady dividend payer with some intriguing upside in robotics-assisted surgery.

fool.com · 6 jul

Is Bristol Myers Squibb's 4.3% Dividend Yield Safe? Here's What Investors Need to Know.

Bristol Myers Squibb is generating more than enough earnings to cover its dividend right now. However, the company faces a daunting patent cliff.

seekingalpha.com · 3 jul

Bristol Myers Squibb: Pain First, Payoff Later?

Bristol Myers Squibb remains a Strong Buy, supported by steady performance and undervaluation despite recent underperformance versus the benchmark. BMY boasts a 4.43% forward dividend yield, over 2.7x the sector median, with 36 years of uninterrupted payments and 18 years of consecutive growth. Recent double-beat earnings and consistent estimate beats since 2024 reinforce positive sentiment and justify a premium valuation.

seekingalpha.com · 3 jul

Bristol-Myers Squibb: Cash Flow Machine, Outsized Growth Portfolio, And Inflation Beating Incomes

BMY's growth portfolio now comprises 54.1% of revenues and delivered +9% YoY growth in FQ1'26 against the legacy portfolio's slower erosion, supporting further upside to the currently conservative FY2026 guidance. Strategic partnerships with Jiangsu Hengrui, accretive M&As, and strong uptake of Opdivo Qvantig underpin the company's multi-pronged portfolio renewal efforts, despite the near-term IPRD noise. BMY's intermediate-term top/bottom-line growth prospects are likely to underwhelm due to LOE risks from Eliquis/Opdivo, albeit with secure dividend payouts at 39.2% of free cash flow.

zacks.com · 1 jul

Bristol Myers Squibb Company (BMY) Is a Trending Stock: Facts to Know Before Betting on It

Bristol Myers (BMY) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

fool.com · 1 jul

Bristol Myers Squibb vs. Johnson & Johnson: Which Healthcare Stock Is a Better Buy in 2026?

Bristol Myers Squibb focuses on specialized medicines in oncology and immunology, and shares sport a low valuation. Johnson & Johnson offers a diversified business model spanning innovative medicines and medical technology.